All In Biotech

Drug Trial Radar · NCT05588531

Study on Tolerance, Pharmacokinetics and Drug Interaction of YK-1169 in Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Oct 20, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

66

Actual

Start

Dec 20, 2021

Primary completion

Apr 2, 2022

Study completion Apr 8, 2022

Sponsor

Sponsor type
Industry
First posted
Oct 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Factorial
Masking
Triple (participant, care provider, investigator)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate the safety and tolerability of multiple doses of YK-1169 in healthy subjects, the pharmacokinetic characteristics of multiple doses in healthy subjects, and the drug interaction between cefepime and avibactam.

Conditions

  • Pharmacokinetics

Interventions

  • Group 1:YK-1169Drug

    YK-1169 0.5g (containing cefepime 0.4g, avibactam 0.1g) single intravenous infusion for 2 hours

  • Group 2:YK-1169/Placebo InjectionDrug

    YK-1169 1.25g (containing cefepime 1.0g, avibactam 0.25g) / placebo single intravenous infusion for 2 hours

  • Group 3:YK-1169/PlaceboDrug

    On the first day, YK-1169 2.5 g (containing cefepime 2.0 g, avibactam 0.5g) was single intravenously infused for 2 h. On the third day, YK-1169 2.5 g (containing cefepime 2.0 g, avibactam 0.5g) was single intravenous infusion for 2 h, three times a day at 8-h intervals, until the morning dose on the tenth day

  • Group 4:YK-1169/PlaceboDrug

    On the first day, YK-1169 3.75 g (containing cefepime 3.0 g, avibactam 0.75g) was single intravenously infused for 2 h. On the third day, YK-1169 3.75 g (containing cefepime 3.0 g, avibactam 0.75g) was single intravenous infusion for 2 h, three times a day at 8-h intervals, until the morning dose on the tenth day

  • Group 5:YK-1169/Placebo InjectionDrug

    YK-1169 5.0g (containing cefepime 4.0g, avibactam 1.0g) / placebo single intravenous infusion for 2 hours

  • Group 6:YK-1169/Cefepime hydrochloride for injection/Avibactam for injectionDrug

    YK-1169 2.5g (containing cefepime 2.0g, avibactam 0.5g)/cefepime hydrochloride for injection 2.0g/avibactam for injection 0.5g, three-cycle three-cross single intravenous infusion for 2 hours

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. According to Common Terminology Criteria for Adverse Events Version 5.0, the incidence and frequency of AEs and SAEs will be statistically analyzedTime frame: Through study completion, an average of 1 month.
  2. clinical adverse eventsTime frame: Through study completion, an average of 1 month.
  3. body temperature (frontal temperature)Time frame: Through study completion, an average of 1 month.
  4. PulseTime frame: Through study completion, an average of 1 month.
  5. sitting blood pressureTime frame: Through study completion, an average of 1 month.
  6. physical examinationTime frame: Through study completion, an average of 1 month.
  7. laboratory testsTime frame: Through study completion, an average of 1 month.
  8. 12-lead ECGTime frame: Through study completion, an average of 1 month.
  9. premature withdrawalTime frame: Through study completion, an average of 1 month.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • 辛玉霞

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.